No Data
No Data
Hong Kong stock market fluctuations | Yimingangke-B (01541) rose more than 20% in the middle of the trading day, the clinical trial of IMM01 combined with Toripalimab completed the first administration.
Zhī tōng cáijīng APP learned that Yiming Aungke - B (01541) rose more than 20% in intraday trading. As of the time of publication, it has risen 12.4% to HKD 14.5, with a turnover of HKD 6.1465 million. On the news side, Yiming Aungke issued an announcement that on July 1, 2024, the company successfully completed the first patient dose of the III phase clinical trial of R / R classical Hodgkin's lymphoma (cHL) patients who relapsed or progressed difficulty after treatment with IMM01 (tidapreparsi-pamoate) and toreremycin monoclonal antibody combined treatment procedure program cell death protein 1 (PD-1) inhibitor. In addition, the company
ImmuneOnco Doses First Patient in Phase 3 Clinical Trial of Hodgkin Lymphoma Drug
ImmuneOnco Biopharmaceuticals (HKG:1541) successfully dosed the first patient in the phase III clinical trial of IMM01 (timdarpacept) in combination with tislelizumab, a Wednesday bourse filing said.
IMM01 (Tirapazamine) with Trastuzumab Combination Therapy Clinical Trial Update for Yimingangco-B (01541.HK)
On July 3, Grong Hui announced that Yiming Angke-B (01541.HK) successfully administered the first dose to a patient in Phase III clinical trial for PD-1 inhibitor treatment with IMM01 (tirapazamine) and tabrelizumab for relapsed or refractory (R/R) classical Hodgkin's lymphoma (cHL) with recurrence or progression after treatment.
ImmuneOnco Biopharmaceuticals Gets IND Approval for NMOSDs Drug Trial in China
ImmuneOnco Biopharmaceuticals (HKG:1541) has obtained investigational new drug (IND) approval for the Phase Ib/III clinical trial of IMC-002 from China's National Medical Products Administration, a Ju
Yimingangke-B (01541): The National Medical Products Administration has approved the clinical trial of a new drug, IMC-002, for the treatment of spectrum diseases associated with optic neuritis and myelitis in Phase Ib/III.
Yimingang Science and Technology Group (01541) announced that the group has obtained the approval of China's National Medical Products Administration (NMPA) ...
Express News | ImmuneOnco Biopharmaceuticals Shanghai Inc - Obtained Investigational New Drug Approval for Phase Ib/III Clinical Trial of Imc-002 From Nmpa
No Data